These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 1810450)

  • 21. [Our experience in the treatment of superficial cancer of the bladder with BCG].
    Martínez E; Díaz I; Salvador J; Viladoms JM; Zungri E; Solé-Balcells FJ
    Arch Esp Urol; 1989 May; 42(4):325-7. PubMed ID: 2782959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BCG in bladder cancer.
    Meek D
    Nurs Times; 1994 Oct 26-Nov 1; 90(43):34-5. PubMed ID: 7984457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Theoretical and experimental evidence on the use of glycosaminoglycans in BCG-mediated immunotherapy of superficial bladder cancer.
    Schamhart DH; De Boer EC; Vleeming R; Kurth KH
    Semin Thromb Hemost; 1994; 20(3):301-9. PubMed ID: 7824966
    [No Abstract]   [Full Text] [Related]  

  • 25. Multicenter study of the BCG Tokyo strain for intravesical treatment in patients with superficial bladder cancer. BCG Study Group.
    Aso Y; Akaza H; Kameyama S; Niijima T
    Prog Clin Biol Res; 1989; 303():383-91. PubMed ID: 2675000
    [No Abstract]   [Full Text] [Related]  

  • 26. [The need of prolonged BCG treatment in superficial bladder cancer is suggested by the development of a peripheral immune response induced by BCG].
    Shekarsarai H; Zlotta AR; Drowart A; Van Vooren JP; De Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
    Acta Urol Belg; 1997 Mar; 65(1):1-4. PubMed ID: 9245197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravesical bacillus Calmette-Guérin (BCG) in superficial bladder tumors. An overview.
    Debruyne FM; Witjes JA; vd Meijden AP
    Arch Esp Urol; 1990; 43 Suppl 2():133-8. PubMed ID: 2096774
    [No Abstract]   [Full Text] [Related]  

  • 28. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
    de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
    J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Future clinical research on the use of BCG for bladder cancer.
    Morales A; Nickel JC
    Prog Clin Biol Res; 1989; 310():361-9. PubMed ID: 2771995
    [No Abstract]   [Full Text] [Related]  

  • 30. BCG-RIVM: a new BCG preparation for intravesical immunotherapy of superficial bladder cancer.
    Schreinemachers L; Van der Meyden A; Steerenberg P; Feitz W; Groothuis D; De Jong W; Debruyne F
    Chemioterapia; 1987 Jun; 6(2 Suppl):713-6. PubMed ID: 3334665
    [No Abstract]   [Full Text] [Related]  

  • 31. Bacillus Calmette-Guérin and superficial bladder cancer. Clinical experience and mechanism of action.
    Catalona WJ; Ratliff TL
    Surg Annu; 1990; 22():363-78. PubMed ID: 2408170
    [No Abstract]   [Full Text] [Related]  

  • 32. Complications of bacillus Calmette-Guerin (BCG) immunotherapy in superficial bladder cancer.
    Sosnowski JT
    Compr Ther; 1994; 20(12):695-701. PubMed ID: 7882653
    [No Abstract]   [Full Text] [Related]  

  • 33. [Preventive treatment of superficial tumors of the bladder using intravesical BCG. Review].
    Patard JJ; Chopin DK
    Ann Urol (Paris); 1993; 27(1):24-30. PubMed ID: 8470876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose BCG-Pasteur strain in the treatment of superficial bladder cancer: preliminary results.
    Pagano F; Bassi P; Milani C; Meneghini A; Tuccitto G; Garbeglio A; Guazzieri S
    Prog Clin Biol Res; 1989; 310():253-61. PubMed ID: 2672015
    [No Abstract]   [Full Text] [Related]  

  • 35. [BCG in the treatment of superficial transitional cell carcinoma of the urinary bladder].
    Leibovici D; Zisman A; Lindner A
    Harefuah; 1999 Apr; 136(8):628-33. PubMed ID: 10955074
    [No Abstract]   [Full Text] [Related]  

  • 36. Use of Bacillus Calmette-Guerin in superficial bladder cancer: a review.
    Talug C; Brown ET; Zaslau S; Kandzari SJ
    W V Med J; 2009; 105(3):17-9. PubMed ID: 19456033
    [No Abstract]   [Full Text] [Related]  

  • 37. [The influence over the long-term prognosis of BCG therapy and the surgical treatment in superficial bladder cancer treatment].
    Higashi S; Matsui Y; Takahashi T; Nishiyama H; Ito N; Yamamoto S; Kamoto T; Ogawa O
    Hinyokika Kiyo; 2005 Aug; 51(8):529-31. PubMed ID: 16164268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Assessment of 8-hydroxy-2'-deoxyguanosine concentrations in bladder cancer patients treated with intravesical BCG instillation].
    Kaczmarek P; Błaszczyk J; Fijałkowski P; Sierakowska-Fijałek A; Niemirowicz J; Kasprzak A; Baj Z
    Pol Merkur Lekarski; 2005 Oct; 19(112):526-8. PubMed ID: 16379317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of superficial bladder carcinoma with BCG. Long term follow-up.
    Martínez-Piñeiro JA
    Prog Clin Biol Res; 1984; 162B():335-45. PubMed ID: 6438642
    [No Abstract]   [Full Text] [Related]  

  • 40. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale and design of the trial of the Southeast Co-operative Urological Group, The Netherlands.
    van der Meijden PM; Debruyne FM; Steerenberg PA; de Jong WH; Doesburg W
    Prog Clin Biol Res; 1989; 310():285-98. PubMed ID: 2505272
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.